Vanguard Group Inc. Acquires 10,817 Shares of Amedisys, Inc. (NASDAQ:AMED)

Vanguard Group Inc. boosted its holdings in shares of Amedisys, Inc. (NASDAQ:AMED) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,216,120 shares of the health services provider’s stock after purchasing an additional 10,817 shares during the period. Vanguard Group Inc. owned about 9.82% of Amedisys worth $291,992,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Alpine Associates Management Inc. grew its holdings in shares of Amedisys by 3.2% in the 4th quarter. Alpine Associates Management Inc. now owns 888,120 shares of the health services provider’s stock worth $80,632,000 after purchasing an additional 27,403 shares during the last quarter. Wealthfront Advisers LLC bought a new stake in Amedisys during the fourth quarter worth about $72,970,000. Magnetar Financial LLC increased its holdings in shares of Amedisys by 0.3% during the fourth quarter. Magnetar Financial LLC now owns 637,443 shares of the health services provider’s stock worth $57,873,000 after buying an additional 1,835 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Amedisys by 1.3% in the third quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock valued at $54,746,000 after acquiring an additional 7,071 shares during the last quarter. Finally, Pacer Advisors Inc. grew its position in Amedisys by 11,621.9% during the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after acquiring an additional 553,435 shares during the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

Amedisys Stock Performance

Shares of Amedisys stock opened at $91.89 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The firm has a 50 day simple moving average of $92.31 and a 200 day simple moving average of $92.32. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The firm has a market cap of $3.01 billion, a P/E ratio of 36.46, a P/E/G ratio of 1.78 and a beta of 0.76.

Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $598.05 million during the quarter, compared to analyst estimates of $602.38 million. Sell-side analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $101.00.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.